These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732 [TBL] [Abstract][Full Text] [Related]
12. Subthreshold Amyloid Predicts Tau Deposition in Aging. Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045 [TBL] [Abstract][Full Text] [Related]
13. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia. Yew B; Nation DA; Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149 [TBL] [Abstract][Full Text] [Related]
14. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. Landau SM; Breault C; Joshi AD; Pontecorvo M; Mathis CA; Jagust WJ; Mintun MA; J Nucl Med; 2013 Jan; 54(1):70-7. PubMed ID: 23166389 [TBL] [Abstract][Full Text] [Related]
15. Parental History of Memory Impairment and β-Amyloid in Cognitively Unimpaired Older Adults. Seto M; Hohman TJ; Mormino EC; Papp KV; Amariglio RE; Rentz DM; Johnson KA; Schultz AP; Sperling RA; Buckley RF; Yang HS JAMA Neurol; 2024 Aug; 81(8):798-804. PubMed ID: 38884955 [TBL] [Abstract][Full Text] [Related]
16. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW; Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939 [TBL] [Abstract][Full Text] [Related]
17. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823 [TBL] [Abstract][Full Text] [Related]
18. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095 [TBL] [Abstract][Full Text] [Related]
19. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ; Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494 [TBL] [Abstract][Full Text] [Related]
20. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Guo T; Shaw LM; Trojanowski JQ; Jagust WJ; Landau SM; Neurology; 2020 Oct; 95(15):e2075-e2085. PubMed ID: 32759202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]